All In Biotech

Drug Trial Radar · NCT04255277

To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

A Single-center, Double-blind for Cenerimod, Open-label for Moxifloxacin, Placebo-controlled, Parallel-group, Randomized Study in Healthy Male and Female Subjects to Investigate I: the Effect of Cenerimod on the QTc Interval II: the Effect of Cenerimod on the Pharmacokinetics of Combined Oral Contraceptives III: the Effect of Charcoal on the Pharmacokinetics of Cenerimod.

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

97

Actual

Start

Jan 31, 2020

Primary completion

Sep 14, 2021

Study completion Oct 18, 2021

Sponsor

Lead sponsor
Viatris Innovation GmbHIndustry
Sponsor type
Industry
First posted
Feb 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, double-blind for cenerimod, open-label for moxifloxacin, placebo- and moxifloxacin-controlled, parallel-group study to investigate the effect of cenerimod on the duration of the QT interval in healthy male and female participants. Participants will be randomly assigned to one of the 4 treatments: placebo, cenerimod 0.5 mg, cenerimod 4 mg or moxifloxacin.

Conditions

  • Healthy Subjects

Interventions

  • Combined oral contraceptives (COC)Drug

    A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.

  • Moxifloxacin 400mgDrug

    A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.

  • Cenerimod 0.5 mgDrug

    This will be administered orally as a film-coated tablet in the morning.

  • Cenerimod 4 mgDrug

    This will be administered orally as a film-coated tablet in the morning.

  • Charcoal, activatedOther

    Granules for oral suspension will be used and administered open-label.

  • Matching PlaceboDrug

    Cenerimod matching placebo tablets will be administered once daily orally in the morning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Placebo-corrected, change-from-baseline QTcF (ΔΔQTcF)Time frame: Day 6, 7, 14, 21, 35, and 56.
  2. Maximum plasma concentration (Cmax): levonorgestrelTime frame: Day 1 to Day 3; Day 42 to Day 44
  3. Maximum plasma concentration (Cmax): ethinylestradiolTime frame: Day 1 to Day 3; Day 42 to Day 44
  4. Time to reach Cmax (tmax): levonorgestrelTime frame: Day 1 to Day 3; Day 42 to Day 44
  5. Time to reach Cmax (tmax): ethinylestradiolTime frame: Day 1 to Day 3; Day 42 to Day 44
  6. The area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf): levonorgestrelTime frame: Day 1 to Day 3; Day 42 to Day 44
  7. The area under the plasma concentration-time curve (AUC) from zero to t (AUC0-t): levonorgestrelTime frame: Day 1 to Day 3; Day 42 to Day 44
  8. The area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf): ethinylestradiolTime frame: Day 1 to Day 3; Day 42 to Day 44
  9. The area under the plasma concentration-time curve (AUC) from zero to t (AUC0-t): ethinylestradiolTime frame: Day 1 to Day 3; Day 42 to Day 44
  10. Terminal elimination half-life (t1/2): levonorgestrelTime frame: Day 56 to Day 68
  11. Terminal elimination half-life (t1/2): ethinylestradiolTime frame: Day 56 to Day 68
  12. Terminal elimination half-life (t1/2): cenerimodTime frame: Day 56 to Day 68
  13. Area under the plasma concentration-time curve (AUC) from Day 56 to infinity (AUC56-inf) for cenerimodTime frame: Day 56 to Day 68

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site 1

    Rennes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.